In the world of oncology, HER2 (human epidermal growth factor receptor 2) used to represent a simple boundary—positive meant eligibility for treatment; negative meant no access to targeted therapy.. However, with the advent of antibody-drug conjugates (ADCs), this boundary has begun to blur. This article published in Gynecologic Oncology illustrates that:HER2 is no longer a … Read more
Introduction The field of anti-tumor treatment in China has reached a significant milestone—the first domestically developed HER2 antibody-drug conjugate (ADC) Botuzumab (Shutai Lai®) for the treatment of HER2 positive breast cancer, which can be widely used in second-line and above therapies, has been prescribed in multiple top hospitals across the country.This marks the official entry … Read more
Author｜YY 01 Focus on the ADC signals The discussion at the 2025 European Society for Medical Oncology (ESMO) annual meeting once again centered on antibody-drug conjugates (ADCs). After over a decade of clinical accumulation, ADCs are gradually moving from treatment for metastatic and advanced tumors into earlier stages of disease. At this year’s conference, AstraZeneca … Read more
Introduction In the field of cancer treatment, antibody-drug conjugates (ADCs) are hailed as “biological missiles” that can precisely deliver high concentrations of chemotherapy drugs to tumor cells, enhancing efficacy while reducing damage to normal tissues. Among them, trastuzumab deruxtecan (T-DXd, also known as DS-8201), which targets the HER2 protein, has become a significant breakthrough in … Read more
Abstract: Brain metastases (BMs) from lung cancer are one of the major factors contributing to poor prognosis in patients with non-small cell lung cancer (NSCLC). In recent years, antibody-drug conjugates (ADCs) have emerged as a new hope for treating HER2-mutant NSCLC due to their precise targeting and potent anti-tumor activity. This article focuses on the … Read more
The emergence of T-DXd represents a significant breakthrough in the treatment of HER2-positive and HER2-low expressing breast cancer. However, like any effective anti-cancer therapy, acquired resistance remains a major challenge affecting the long-term benefits for patients. Since the launch of Trastuzumab emtansine in 2013, five HER2 ADCs have been approved:Table 1: Approved HER ADCsAs clinical … Read more
Introduction Breast cancer is one of the most common malignant tumors among women worldwide and is also a leading cause of cancer-related deaths. According to the data released in the “2022 Global Cancer Statistics Report”, there were approximately 20 million new cancer cases globally, with women accounting for 9.7 million, and breast cancer accounting for … Read more
This study was led by Professor Guo Jun and Professor Sheng Xi Nan from Peking University Cancer Hospital, and the results have been published in the prestigious international journal The New England Journal of Medicine, and presented at the European Society for Medical Oncology (ESMO) conference. Core Efficacy Data: Significant Extension of Survival This study … Read more
Recently, Professor Jeremiah A. Johnson from the Massachusetts Institute of Technology and his research team proposed a targeted cancer therapy using antibody–bottlebrush prodrug conjugates(Antibody-Bottlebrush Prodrug Conjugates, ABC). This research was published in the international academic journal Nature Biotechnology on September 9, 2025. A summary of this article and expert/editorial opinions were also published in the … Read more
Global Analysis of ADC Drugs: Popular, Emerging Targets and Star Drugs The human epidermal growth factor receptor2 (HER2) is one of the most extensively studied and fruitful targets in ADC drugs.HER2 belongs to the ERBB receptor tyrosine kinase family and is overexpressed or amplified in various epithelial-derived tumors, including breast cancer, gastric cancer, and non-small … Read more